Reply  by Gheeraert, Peter & Henriques, José P.S
Allow me to ensure you that pharmacy curriculums do not provide
background as an insurance broker, nor do pharmacists desire to be
in such a position. This environment is one of the principle reasons
for the current shortage of retail pharmacists. This is heightened by
the standardization of the Doctor of Pharmacy degree and its
replacement of the Bachelor of Science curriculums nationwide.
Pharmacists today go through 6 to 7 years of education whose
foundation prepares students to practice pharmaceutical care in a
clinical setting. It is nothing short of degrading to be forced by
Managed Care to assume responsibility for poor medical decisions
justified by business cases.
So, allow me to assure you as a pharmacist that I am equally
frustrated by the constraints of Managed Care on the clinician’s
ability to decide what is best for the patient. However, change will
only be achieved when Managed Care is forced to change. Perhaps
this is an endeavor on which physicians and pharmacists should
collaborate since the goal of both professions is to optimize patient
care.
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Coronary Anatomy in Acute
Myocardial Infarction Patients
With Sudden Out-Of-Hospital Death
The recent article by Gheeraert et al. (1) was interesting and
thought-provoking. The authors suggested that acute occlusion of
the left-side coronary vessels (left anterior descending [LAD] or
left circumflex [Lcx] arteries) increases the risk of out-of-hospital
ventricular fibrillation (VF) in acute myocardial infarction (AMI)
patients. The study was designed so that they compared patients
who were successfully resuscitated from VF found to be due to
AMI and AMI patients without VF. Their conclusions, however,
raise points of criticism.
The resuscitated patients they studied with angiography were
those in whom there was a reasonably short period from the loss of
consciousness to the beginning of resuscitation to assure that these
patients had a chance of surviving without major neurologic
deficits. The authors also discuss the possible limitation by
selection bias because a great majority of patients with out-of-
hospital VF fall short of reaching their series (2). However, they
hypothesize that there is no bias without referring to previous
studies on sudden cardiac death (SCD) victims.
The authors found that only 15% of occlusions in those AMI
patients succesfully resuscitated from VF were situated in the right
coronary artery (RCA). This finding is contradicted by the fact
that numerous studies on SCD victims with AMI have shown that
RCA is the culprit occluded artery in 40 to 50% of cases (2–5).
One study even addressed the issue of coronary and myocardial
findings in SCD victims compared with hospital AMI patients (3)
and found that inferior infarctions and RCA occlusions were more
frequent in SCD victims.
It is, thus, highly likely that the results of Gheeraert et al. (1) are
the consequence of selection bias. Their conclusion that RCA
occlusion is associated with decreased risk of arrhythmia is also
highly speculative in light of the patient selection and the results of
previous studies on SCD. In asymptomatic individuals who suffer
AMI, the degree of the underlying coronary disease is the most
severe in the left-sided vessels, especially LAD (6). Thus, collat-
erals are possibly more frequently supplying the myocardium
normally fuelled by LAD, and the total occlusion of RCA is likely
to be associated with severe arrhythmic response in the absence of
significant collaterals (7).
The major conclusion from the results presented in the study by
Gheeraert et al. is that left-side coronary occlusion may, in fact, be
associated with decreased risk of dying suddenly in the acute phase
of AMI and select individuals who are more likely to be resusci-
tated succesfully by the paramedics and ultimately reach the
hospital and qualify for study series, such as the one commented on
here.
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REPLY
We thank J. Mikkelsson for his comments on our article (1). The
authors would like to take this opportunity to discuss the effects of
patient selection and points of interest in more detail when our
results are compared with studies on sudden cardiac death (SCD).
We studied out-of-hospital ventricular fibrillation (VF) in the
early phase of acute myocardial infarction (AMI). To compare our
study with studies on SCD, two main points deserve attention.
First, we focused on the early phase of AMI. In victims of SCD
identification of subjects that were in the early phase of AMI is
extremely challenging. Standard histological techniques underes-
timate the true frequency of early AMI. The articles on SCD cited
by Mikkelsson confirmed that only 5 to 21% of victims were in the
early phase of AMI. Presence of a fresh coronary occlusion or
ruptured plaque also varied between 23 and 82%, reflecting
heterogeneity of methodology or studied populations. Diagnosis of
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early phase of AMI in our study was based on ST segment
elevation and angiographically confirmed presence of a fresh
coronary occlusion. Identical criteria were applied for the control
group. Second, we specifically focused on VF and not on all fatal
arrhythmias as a whole. Severe bradyarrhythmias are reported up
to 30% in SCD (2). In studies on SCD the fatal arrhythmia is
seldom specified. In our study VF was confirmed by rhythm
recordings. So, studies on SCD are impossible to compare with our
study as long as VF, early phase of AMI and coronary anatomy are
not simultaneously specified.
The main finding of our study was that acute occlusion in the
left coronary artery is associated with greater risk for out-of-
hospital VF compared with the right coronary artery in the early
phase of AMI. This finding is not the result of differential
selection. We fully agree that the AMI patients in our study do not
represent all patients with AMI. To reach the group of “AMI with
VF,” patients had to survive VF. To explain our findings by
selection bias, as suggested by Mikkelsson, one has to assume that
patients with out-of-hospital VF and occlusion of left coronary
artery have a higher probability of being admitted than patients
with out-of-hospital VF and occlusion of right coronary artery. To
the best of our knowledge, there are no data suggestive of this
assumption.
The comments of Mikkelsson and our article raise another
important field of interest: What is the effect of site of occlusion on
life-threatening bradyarrhythmias in the early phase of AMI?
Therefore, studies on SCD that document bradyarrhythmias, early
phase of AMI and coronary anatomy would be very interesting.
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Underestimation of the
Valvulopathy Effect of Fenfluramine
In an effort to evaluate the relationship between the use of
fenfluramines as diet drugs and the prevalence of mitral valve and
aortic valve regurgitation, Burger et al. (1) compared measure-
ments from a study conducted for another purpose to those
described by Singh (2). Burger observed that the prevalence of
mitral valvulopathy in his study was comparable with the Framing-
ham study (1.3% vs. 1.6% from Framingham) and aortic regurgi-
tation (6.6% vs. 4.8% from the Framingham study). Burger
surmised that the valvulvar regurgitation seen in his patients may
not be due to fenfluramine but to age-related degenerative
changes. Schiller (3), in an accompanying editorial, seconds this
point of view stating (page 1161), “It would seem then that as
studies have become more scientifically rigorous, the role of
fen/phen in valve disease appears to be approaching the vanishing
point.” However, there are two important additional observations
concerning Burger’s methodology that undermine these conclu-
sions.
There were 591 patients in Burger’s study. Of these patients,
only 226 (38.2%) returned for an echocardiogram. The remaining
365 patients who were also exposed to the fenfluramines, for
unknown reasons, did not undergo echocardiography. Since only
three of the 226 patients who returned had mitral regurgitation,
and only 15 of the 226 patients had aortic regurgitation, the fate of
the remaining 365 patients is critical in a proper assessment. The
absence of the echocardiograms in over 60% of the cohort makes
this study especially vulnerable to selection bias.
A second concern involves Burger’s simple comparison between
regurgitation prevalence in his population and Framingham. The
difference in the mean ages between that of Burger’s cohort (mean
age 46.9, standard deviation 8.9) and that of the Framingham
population (mean age 55, standard deviation 10) suggests that a
coarse comparison of the crude prevalences from these two
populations is inappropriate and misleading. Fortunately a more
appropriate adjustment is available through an examination of
Singh’s data (4). Given both the mean age (standard deviation) and
the gender distribution provided by Burger one can, assuming the
normal distribution, approximate the distribution of age and
gender in the Burger study. From Singh (4) the prevalence of each
of mitral regurgitation and aortic regurgitation is available
(Table 1).
From Table 1 one can compute the expected prevalence in the
Burger cohort based on the gender and age-specific mitral and
aortic valve prevalence in the Framingham study. If the 10.2% of
patients whose ages are outside the 26 to 83 age range (based on
a normal distribution with mean age 46.9 and standard deviation
8.9) fall in the upper age range (greater than 83) and these patients
have the same prevalence of valvular regurgitation as those in the
70 to 83 age range, the computations reveal that the expected
prevalence for mitral regurgitation (Food and Drug Administra-
tion criteria) is 1.0% and for aortic regurgitation is 3.3%. This
conservative computation provides mitral and aortic prevalences
that are less than those observed by Burger. Based on these age-
and gender-adjusted prevalences, the prevalences seen by Burger et
al. are greater than would be expected from degenerative changes
alone.
These two observations substantially weaken the explanation
provided by Burger. Since Schiller chose to build his conclusions
on Burger’s results, this editorial’s foundation is now effectively
removed. The data collected by Burger, while representing an
incomplete assessment, support, rather than refute, the association
found between fenfluramine and cardiac valvulopathy.
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